Not sure why government is supporting VT-464. Googled it and apart of many attempts in different cancers and trials it all seemed to have failed.
Now targeting HER2, the space IMU has achieved the best results with HER-Vax and now combining with Pfizer and Merck targeting gastric cancer varieties.
Not an expert, but looks to me $5m wasted.
Would be better value supporting IVX or IMU.
GLTA
Ann: Complete Regression of TNBC Tumours and Protective Immunity, page-234
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.43M | |||
| Open | High | Low | Value | Volume |
| 13.5¢ | 14.0¢ | 12.5¢ | $74.92K | 574.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 54000 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 61 | 1 |
View Market Depth
| Last trade - 13.01pm 16/06/2025 (20 minute delay) ? |
| IVX (ASX) Chart |